Analyst Recommended Stock: Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

The company is trading up by 1.27% since yesterday’s close of $121.01. The shares ended last trade at $105.4, implying that Wall Street analysts see shares climbing about 33.63 per cent in 12 months’ time. While some stocks are sharply higher, others – such as Lumber Liquidators Holdings Inc (NYSE:LL) and Zimmer Biomet Holdings Inc (NYSE:ZBH) – are tanking. The company has its outstanding Shares of 200.01 Million. It has a 94.28 P/E ratio. Earlier the firm had a rating of “Buy ” on the company shares. The number of shares now owned by investors are 226.47 mln.

Zimmer Biomet, based in Warsaw, Ind., blamed the shortfall on problems within its supply chain that prevented it from meeting customer demand for its artificial hip- and knee-joint replacement products.

Zimmer Biomet Holdings has 200,012,000 shares in issue which have a share price of 105.97 giving Zimmer Biomet Holdings a market capitalisation of 21.20B Dollars. Year to Date performance value (YTD perf) value is 3.38%.

Return on Assets (ROA) for Zimmer Biomet Holdings, Inc. (NYSE:ZBH) went down -0.07% during trading on 10/27/2016, with the company’s shares hitting the price near $120.99. A dividend is a distribution of a portion of a company’s earnings decided by its BOD (board of directors) specifically for its shareholders. Finally, JPMorgan Chase & Co. upped their price target on shares of Zimmer Biomet Holdings from $134.00 to $148.00 and gave the stock an “overweight” rating in a research report on Friday, July 29th. NYSE:ZBH Medical Appliances & Equipment is 2.4 and the Quick Ratio measures to be 1.5. ZBH has Average True Range for 14 days of 3.48. (ZBH) updated its full-year 2016 constant currency income and adjusted eps guidance.

The stock has a 1-year performance up 6.11% and a positive weekly performance at 1.53%. (NYSE:ZBH) is 20.21 percent while its Performance (Week) is -3.9 percent and Performance (month) is at -4.14 percent.

Let’s have a look at some of the important valuation ratios of the Zimmer Biomet Holdings, Inc.

Analyst Rating on Zimmer Biomet Holdings, Inc. Similarly, 16 of 23 analysts rate ZBH a “buy” or better, compared to seven “hold” opinions and not a single “sell”.

Price Potential: Even though the stock has posted -13.99% fall in value, its new closing price reflects a -20.88% fall in value from company’s one year high of $133.21. One analyst has rated the stock with a sell rating, two have issued a hold rating, twenty have issued a buy rating and one has given a strong buy rating to the stock.

In the third quarter, knee-implant revenue edged down 0.1% to $631 million, below the $649 million forecast by analysts, according to FactSet.

Zimmer cut the high end of its full-year earnings outlook, saying it now expects to put up adjusted EPS of $7.90 to $7.95, down from prior guidance of $7.90 to $8.00.